

Patrick Marcellin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1892611/patrick-marcellin-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29
papers

5,111
citations

21
h-index

30
g-index

30
ext. papers

6,030
ext. citations

11.4
avg, IF

5.26
L-index

#	Paper	IF	Citations
29	Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. <i>Lancet, The</i> , 2013 , 381, 468-75	40	1128
28	Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. <i>New England Journal of Medicine</i> , 2004 , 351, 1206-17	59.2	904
27	Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. <i>New England Journal of Medicine</i> , 2008 , 359, 2442-55	59.2	897
26	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 196-206	18.8	259
25	Combination of Tenofovir Disoproxil Fumarate and Peginterferon α 2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016 , 150, 134-144.e10	13.3	219
24	Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. <i>Liver International</i> , 2018 , 38 Suppl 1, 2-6	7.9	207
23	Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. <i>Gastroenterology</i> , 2014 , 147, 132-142.e4	13.3	207
22	Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1457-64	4	196
21	Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. <i>Liver International</i> , 2016 , 36 Suppl 1, 47-57	7.9	174
20	Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. <i>Hepatology</i> , 2006 , 44, 728-35	11.2	174
19	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Cancer</i> , 2015 , 121, 3631-8	6.4	125
18	Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. <i>Liver International</i> , 2018 , 38 Suppl 1, 7-13	7.9	91
17	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017 , 66, 39-47	13.4	80
16	HBsAg quantification: useful for monitoring natural history and treatment outcome. <i>Liver International</i> , 2014 , 34 Suppl 1, 97-107	7.9	79
15	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016 , 64, 1011-1019	13.4	61
14	Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. <i>Liver International</i> , 2011 , 31, 516-24	7.9	55
13	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015 , 62, 41-7 ^{13.4}	13.4	54

12	Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. <i>Liver International</i> , 2019 , 39, 1868-1875	7.9	51
11	HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. <i>Liver International</i> , 2015 , 35 Suppl 1, 82-90	7.9	49
10	Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. <i>Liver International</i> , 2011 , 31 Suppl 1, 122-8	7.9	27
9	Anti-pre-S responses and viral clearance in chronic hepatitis B virus infection. <i>Hepatology</i> , 1992 , 15, 26-31	11.2	24
8	Future treatments for hepatitis delta virus infection. <i>Liver International</i> , 2020 , 40 Suppl 1, 54-60	7.9	18
7	Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1087-1094.e2	6.9	12
6	Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life. <i>Liver International</i> , 2021 , 41, 1509-1517	7.9	8
5	New therapies for hepatitis delta virus infection. <i>Liver International</i> , 2021 , 41 Suppl 1, 30-37	7.9	5
4	Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 964-973 ^{3,4}		3
3	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019 , 19, 300	4	2
2	Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. <i>Digestive and Liver Disease</i> , 2015 , 47, 296-302	3.3	2
1	Update on the Role of Quantitative HBsAg and HBeAg Monitoring during Peginterferon Therapy. <i>Current Hepatitis Reports</i> , 2012 , 11, 75-81		